Cotadutide vs HM15211
Head-to-head comparison of Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) and HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cotadutide | HM15211 |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist | HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist |
| Molecular Weight | ~4,700 Da | N/A |
| Half-Life | Approximately 24 hours | Approximately 1 week |
| Amino Acids | 37 | N/A |
| Typical Dose | 0.3-3 mg daily in clinical studies | Investigational; no established human dose |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 18 | 12 |
| Research Status | Clinical | Clinical |
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
HM15211 Benefits
- ✓appetite suppression
- ✓greater fat oxidation
- ✓weight loss
- ✓improved metabolic markers
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
HM15211 Dosing
once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
HM15211 Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠reduced appetite
Research Overview
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
HM15211
Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.